Stocks · News reference
Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company"))), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Relmada Therapeutics announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference in Boston (September 8-10, 2026). The company is advancing its lead candidates NDV-01 and sepranolone through clinical development, with NDV-01 expected to reach IND filing by year-end 2026 and a Phase 3 RESCUE registrational program planned for initiation.
Filed: 2026-08-06 AccNo: 0001213900-26-086190 Size: 12 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.20) by 45 percent. This is a 63.33 percent increase over losses of $(0.30) per share
Relmada Therapeutics, a clinical-stage biotechnology company, announced its addition to the Russell 2000® and Russell 3000® Indexes effective June 26, 2026. The company's CEO attributed the achievement to robust 12-month data for its lead candidate NDV-01 in NMIBC treatment and a well-capitalized balance sheet.